Mabion Advances MabionCD20 Toward FDA Orphan Drug Status for ITP

Mabion S.A. held a Pre-IND Type B meeting with the FDA, a regulatory step toward filing an IND for MabionCD20 as an orphan drug for immune thrombocytopenia (ITP). The meeting signals progress but does not confirm approval or clinical outcomes. This is a company-specific regulatory milestone with no immediate market-wide impact.